Pascal P.
- Country
- The Netherlands
- Department
- N/A
Research Overview
- Long-Term Safety and Tolerability of Atogepant for Migraine Prevention in Chronic or Episodic Migraine: A Phase 3, 156-Week Extension Study
- A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine
- A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6 to 17 years of age
Data & Insights
Has run more than one trial at 33 of 91 partner sites.
Specializations
Neurotherapeutics and Migraine Care
Pascal Proot is involved in clinical research on migraine, with a clear focus on preventive treatment options for both episodic migraine and chronic migraine in pediatric and broader patient populations.
- Preventive migraine therapy
- Pediatric migraine management
- Long-term tolerability of migraine treatment
His work in this area reflects an interest in expanding therapeutic choices for recurrent headache disorders within neurology.
Breast Cancer and Endocrine-Related Symptom Control
His oncology research includes breast cancer, especially HER2-positive breast cancer, hormone receptor-positive metastatic breast cancer, and triple negative breast cancer, with attention to treatment strategies and supportive care.
- HER2-targeted treatment approaches
- Metastatic breast cancer therapy sequencing
- Moderate to severe vasomotor symptoms
He is also linked to research on fezolinetant for vasomotor symptoms associated with endocrine therapy in women with breast cancer.
Colorectal and Rectal Cancer Treatment
Pascal Proot contributes to studies in rectal cancer, metastatic colorectal cancer, and resected colon carcinoma, with emphasis on postoperative and systemic treatment strategies.
- Adjuvant treatment after rectal cancer surgery
- Therapy optimization in metastatic colorectal cancer
- Survival-focused colon cancer management
His research activity in this field is centered on improving outcomes across localized and advanced colorectal cancer settings.
Hematologic Malignancies
His clinical trial involvement includes chronic lymphocytic leukemia, including patients with relapsed disease, as well as multiple myeloma, with a focus on modern targeted treatment combinations and disease control.
- CLL treatment after prior therapy
- Minimal residual disease-directed care
- Myeloma treatment strategy evaluation
This area of interest highlights his engagement with precision approaches in hematologic oncology.
Thrombosis Prevention and Cancer-Associated Risk
He is also involved in research on venous thromboembolism, particularly in the setting of orthopedic surgery and cancer-associated risk management.
- Individualized thrombosis prophylaxis
- Symptomatic VTE prevention
- Bleeding-risk balanced anticoagulation strategies
His work in this domain supports safer prevention strategies for patients at varying levels of thrombotic risk.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.